Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate

被引:15
作者
Allen, Matthew R. [1 ]
Turek, John J. [1 ,5 ]
Phipps, Roger J. [4 ]
Burr, David B. [1 ,2 ,3 ]
机构
[1] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA
[3] Indiana Univ Purdue Univ, Biomed Engn Program, Indianapolis, IN 46202 USA
[4] Husson Univ, Sch Pharm, Bangor, ME USA
[5] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA
关键词
Bisphosphonates; Bone remodeling; Histomorphometry; Rabbit model; NITROGEN-CONTAINING BISPHOSPHONATES; POSTMENOPAUSAL OSTEOPOROSIS; BONE TURNOVER; MICRODAMAGE ACCUMULATION; CLINICAL-EFFICACY; CORTICAL BONE; FRACTURES; WOMEN; INHIBITION; MECHANISMS;
D O I
10.1016/j.bone.2010.07.011
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Clinical data suggest that reductions in fractures associated with osteoporosis may occur sooner in patients treated with risedronate (RIS) compared to those treated with alendronate (ALN). This could be explained by differences in the time course of turnover suppression between these two bisphosphonates. To determine if differences in the onset of turnover suppression exist between RIS and ALN, female New Zealand white rabbits (total n = 32) were treated with clinically relevant doses of RIS or ALN and then administered different fluorochrome labels weekly for four weeks in order to allow histological assessment of the time-course of turnover suppression. By the third week of treatment vertebral trabecular bone formation rate (BFR/BS) was significantly suppressed with RIS-treatment compared to both VEH and ALN. By the 4th week of treatment, turnover rates in RIS-treated animals remained significantly lower than in VEH-treated animals and were also lower than ALN; at this time-point ALN was significantly lower than VEH. There was no significant reduction in intra-cortical remodeling in the tibial mid-diaphysis at any time point for either RIS or ALN. This greater effect on turnover suppression with RIS early in treatment compared to ALN is likely the result of both risedronate's greater potency on osteoclast inhibition and its lower binding affinity. Together with studies showing more rapid return toward baseline turnover following withdrawal of RIS compared to ALN, this pre-clinical study provides evidence of the differences between bisphosphonates with respect to onset and recovery of bone turnover suppression. This article is part of a Special Issue entitled Bisphosphonates. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:128 / 132
页数:5
相关论文
共 21 条
[1]
Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib [J].
Allen, M. R. ;
Follet, H. ;
Khurana, M. ;
Sato, M. ;
Burr, D. B. .
CALCIFIED TISSUE INTERNATIONAL, 2006, 79 (04) :255-261
[2]
Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment [J].
Allen, Matthew R. ;
Reinwald, Susan ;
Burr, David B. .
CALCIFIED TISSUE INTERNATIONAL, 2008, 82 (05) :354-360
[3]
Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate [J].
Allen, Matthew R. ;
Iwata, Ken ;
Phipps, Roger ;
Burr, David B. .
BONE, 2006, 39 (04) :872-879
[4]
Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial [J].
Black, DM ;
Thompson, DE ;
Bauer, DC ;
Ensrud, K ;
Musliner, T ;
Hochberg, MC ;
Nevitt, MC ;
Suryawanshi, S ;
Cummings, SR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4118-4124
[5]
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years [J].
Bonnick, Sydney ;
Saag, Kenneth G. ;
Kiel, Douglas P. ;
McClung, Michael ;
Hochberg, Marc ;
Burnett, Sherri-Ann M. ;
Sebba, Anthony ;
Kagan, Risa ;
Chen, Erluo ;
Thompson, Desmond E. ;
de Papp, Anne E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (07) :2631-2637
[6]
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: Time-dependent inhibition of human farnesyl pyrophosphate synthase [J].
Dunford, James E. ;
Kwaasi, Aaron A. ;
Rogers, Michael J. ;
Barnett, Bobby L. ;
Ebetino, Frank H. ;
Russell, R. Graham G. ;
Oppermann, Udo ;
Kavanagh, Kathryn L. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (07) :2187-2195
[7]
Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
[8]
Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading [J].
Feher, Anthony ;
Koivunemi, Andrew ;
Koivunemi, Mark ;
Fuchs, Robyn K. ;
Burr, David B. ;
Phipps, Roger J. ;
Reinwald, Susan ;
Allen, Matthew R. .
BONE, 2010, 46 (01) :203-207
[9]
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats [J].
Fuchs, Robyn K. ;
Phipps, Roger J. ;
Burr, David B. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 (10) :1689-1697
[10]
EFFECT OF SEX STEROIDS ON PEAK BONE-DENSITY OF GROWING-RABBITS [J].
GILSANZ, V ;
ROE, TF ;
GIBBENS, DT ;
SCHULZ, EE ;
CARLSON, ME ;
GONZALEZ, O ;
BOECHAT, MI .
AMERICAN JOURNAL OF PHYSIOLOGY, 1988, 255 (04) :E416-E421